波音游戏-波音娱乐城赌球打不开

Submitted by cheukllui3 on
Anti-Cancer
Chemical Biology
Chemistry
Novel tridimensional anticancer agents developed to fight against drug-resistant cancer cells

A research team co-led by chemists from City University of Hong Kong (CityU) recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells. The findings help provide a new direction for anticancer drug development.

Cancer has long been a devastating disease, which affects millions of people worldwide. Despite advances in treatment, current anticancer drugs often have limited effectiveness, lack of cancer selectivity, serious side effects and drug resistance in cancer cells.

“The structure of drugs greatly affects their anticancer performance,” explained Dr. Guangyu Zhu in the Department of Chemistry at CityU. “Most anticancer drugs have planar structures; developing new compounds with tridimensional structures may provide an opportunity to address the limitations of current anticancer drugs.”

In collaboration with researchers from The Hong Kong University of Science and Technology (HKUST), the team tested a new class of tridimensional and chiral compounds, which exhibit promising anticancer activity and present action mechanisms that are distinct from conventional anticancer drugs to overcome drug resistance.

anticancer agents
The half maximal inhibitory concentration (IC50 value) of synthetic lead compounds and clinical drug doxorubicin (DOX) in lung cancer stem cells and normal cells after incubation for 72 hours. Credit: Dr. Guangyu Zhu’s Research Group / City University of Hong Kong

The team first developed a new, highly efficient catalytic synthetic strategy to obtain a novel class of tridimensional and chiral tetraarylmethane compounds that presented better anticancer activity and lower toxicity than the clinical anticancer drug doxorubicin.

In their experiments, the research team tested the compounds with cancer cells in vitro, using doxorubicin as a control. They found that the tetraarylmethane compounds were more cytotoxic to cancer cells, including lung cancer stem cells (LCSCs), which are notorious for their drug resistance to clinical chemotherapeutic drugs, causing treatment failure. The compound also exhibited better cancer cell selectivity as it caused less harm to normal living cells, suggesting lower toxicity.

anticancer agents
SAR analysis of the synthetic compounds. The key factors that
contribute to the anticancer activity of this type of compound are indicated. The presence of certain substituents, including halogen and hydroxyl groups, at certain positions in the tetraarylmethane compounds significantly improves cytotoxicity. TMS, trimethylsilyl; Me, methyl. Credit: ? Tan, X. et al.: https://www.nature.com/articles/s44160-022-00211-4

The team further analyzed the structure-activity relationship of synthesized compounds. They found that the presence of certain substituents, including halogen and hydroxyl groups, at certain positions of the tetraarylmethane compounds significantly improved their cytotoxicity to cancer cells. Upon treatment with the synthesized compound, some cancer cells started to die, as organelle swelling, cell membrane permeabilization, nuclear shrinkage and fragmentation were observed. This suggests that necrotic cell death might have been triggered by the tetraarylmethane compounds.

In the fight against cancer, the majority of anticancer drugs currently available rely on the activation of apoptotic pathways to eliminate cancer cells. However, a promising new avenue of research for reducing drug resistance lies in the development of novel anticancer agents that target alternative cell death pathways. In their experiments, the team found that these innovative compounds induced a different cell death pathway. This suggests that the compounds can bypass the resistance mechanisms generated by conventional drugs, making them highly desirable for further exploration in the field of cancer treatment.

“The satisfactory anticancer performance and unique mechanism make these compounds potential candidates for anticancer agents for further development,” said Dr. Zhu. The team plans to synthesize more compounds and conduct further experiments to evaluate their anticancer performance.

anticancer agents
The synthesised lead compounds induced necroptosis in lung cancer stem cells. The arrows indicate cell membrane permeabilization. Credit: ? Tan, X. et al. https://www.nature.com/articles/s44160-022-00211-4

Their findings were published in the scientific journal Nature Synthesis under the title "Enantioselective synthesis of tetraarylmethanes through meta-hydroxyl-directed benzylic substitution".

The corresponding authors are Dr. Zhu and Professor Jianwei Sun from HKUST. The co-first authors are Dr. Xuefeng Tan from HKUST and Dr. Zhiqin Deng, former postdoc in Dr Zhu’s research group at CityU.

The research received financial support from the National Natural Science Foundation of China, the Science, Technology and Innovation Committee of Shenzhen Municipality, the Hong Kong Research Grants Council, and the Innovation and Technology Commission.

 

This research article originated from CityU Research Stories.

百家乐官网投注方式| 最好百家乐的玩法技巧和规则 | 大亨百家乐官网游戏| tt娱乐城clega| 足球现金网开户| 大发888游戏平台 送1688元现金礼金领取| 百家乐鸿泰棋牌| 百家乐蓝盾假网| k7娱乐| 皇冠平台| 永仁县| 535娱乐城下载| 真人娱乐城送体验金18| 云鼎娱乐场网址| 百家乐软件| 白朗县| 百家乐官网凯时娱乐网| 线上百家乐官网信誉| 百家乐官网前四手下注之观点| 百家乐官网赌场论坛在线| 百家乐官网赌博公司| 百家乐官网桌布9人| 百家乐官网娱乐网会员注册| 云鼎百家乐官网的玩法技巧和规则| 百家乐官网视频画面| 富二代百家乐官网的玩法技巧和规则| 百家乐官网路单| 金海岸百家乐官网的玩法技巧和规则 | 澳门百家乐娱乐平台| 金界百家乐的玩法技巧和规则| 威尼斯人娱乐欢迎您| 百家乐官网美食坊| 澳门百家乐官网海洋阿强| 百家乐官网娱乐平台代理佣金| 澳门百家乐博彩网| 太子百家乐的玩法技巧和规则| 大发888官方888| 澳门美高梅金殿| 澳门百家乐官网游戏说明书| 希尔顿百家乐官网娱乐城 | 欢乐谷线上娱乐|